glimepiride has been researched along with Stroke in 5 studies
glimepiride: structure given in first source
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes." | 5.39 | The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. ( Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P, 2013) |
| "Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
| " We compared the effects of three SU medications and initial SU doses on adverse glycemic and cardiovascular events among NH residents." | 1.91 | Comparative safety of sulfonylureas among U.S. nursing home residents. ( Berry, SD; Hayes, KN; Munshi, MN; Riester, MR; Zullo, AR, 2023) |
| "Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes." | 1.39 | The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. ( Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zullo, AR | 2 |
| Riester, MR | 2 |
| Hayes, KN | 2 |
| Munshi, MN | 2 |
| Berry, SD | 2 |
| Cho, EH | 1 |
| Han, K | 1 |
| Kim, B | 1 |
| Lee, DH | 1 |
| Shannon, RP | 1 |
| Mogensen, UM | 1 |
| Andersson, C | 1 |
| Fosbøl, EL | 1 |
| Schramm, TK | 1 |
| Vaag, A | 1 |
| Scheller, NM | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, G | 1 |
| Køber, L | 1 |
| Darsalia, V | 1 |
| Ortsäter, H | 1 |
| Olverling, A | 1 |
| Darlöf, E | 1 |
| Wolbert, P | 1 |
| Nyström, T | 1 |
| Klein, T | 1 |
| Sjöholm, Å | 1 |
| Patrone, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From the Health Insurance Review and Assessment Service Database[NCT05817097] | 22,119 participants (Anticipated) | Observational | 2023-08-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for glimepiride and Stroke
| Article | Year |
|---|---|
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
Topics: Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agent | 2020 |
DPP-4 inhibition and neuroprotection: do mechanisms matter?
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; L | 2013 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Hypoglyc | 2013 |